Compounds > flucindole
Page last updated: 2024-12-06

flucindole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Flucindole is a synthetic tryptamine derivative that acts as a selective serotonin reuptake inhibitor (SSRI). Its synthesis involves a multi-step process starting from indole-3-acetic acid. Flucindole exhibits antidepressant effects in animal models, potentially due to its ability to increase serotonin levels in the brain. It has been studied for its potential therapeutic use in treating depression, anxiety, and other mood disorders. However, flucindole has not yet been approved for clinical use. Further research is needed to evaluate its safety, efficacy, and potential side effects in humans.'

flucindole: RN given refers to parent cpd with unspecified isomeric designation; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID38531
CHEMBL ID1882682
SCHEMBL ID121717
MeSH IDM0094129

Synonyms (41)

Synonym
flucindole (usan/inn)
D02658
nsc-292826
nsc292826
40594-09-0
mls003115645 ,
1h-carbazol-3-amine,8-difluoro-2,3,4,9-tetrahydro-n,n-dimethyl-
flucindole
3-(dimethylamino)-6,2,3,4-tetrahydrocarbazole
win 35150
smr001831217
6,8-difluoro-n,n-dimethyl-2,3,4,9-tetrahydro-1h-carbazol-3-amine
win-35150
CHEMBL1882682
1h-carbazol-3-amine, 6,8-difluoro-2,3,4,9-tetrahydro-n,n-dimethyl-
flucindolum [inn-latin]
flucindol
3-(dimethylamino)-6,8-difluoro-1,2,3,4-tetrahydrocarbazole
5cyu0d0s8m ,
flucindolum
flucindole [usan:inn]
nsc 292826
unii-5cyu0d0s8m
flucindol [inn-spanish]
SCHEMBL121717
flucindole [inn]
flucindole [usan]
Q5462612
DTXSID40866001
nsc 292826; win 35150
UYM8M8P5MW ,
1h-carbazol-3-amine, 6,8-difluoro-2,3,4,9-tetrahydro-n,n-dimethyl-, (-)-
1h-carbazol-3-amine, 6,8-difluoro-2,3,4,9-tetrahydro-n,n-dimethyl-, (+)-
BT65UC53TM ,
40594-13-6
flucindole, (+)-
flucindole, (-)-
60481-01-8
unii-uym8m8p5mw
unii-bt65uc53tm
AC-36412
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1147086Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 30 to 50 mg/kg, ip1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID1147091Antipsychotic activity in po dosed Sprague-Dawley rat assessed as prevention of d-amphetamine-induced stereotyped behavior measured for 1 min after 90, 100, and 110 mins injection of amphetamine1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID1147088Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 30 mg/kg, ip1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		1.9610aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		1.9510dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
cyclindole
cyclindole: RN given refers to parent cpd; structure		3.7530
ConditionIndicatedRelationship StrengthStudiesTrials
Ptosis, Eyelid
[description not available]		01.9510
Emesis
[description not available]		01.9510
Blepharoptosis
Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.		01.9510
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		01.9510
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510